-> Laminar Pharma was selected as one of the 8 best European projects in the Health Care space by a prestigious panel of 28 directives of pharmaceutical companies and Venture Capital Funds specialized in healthcare investments at the final session of the European Venture Summit, held on the 9th & 10th December 2013 in Düsseldorf (Germany)

-> The presentation made by Vicenç Tur, Laminar Pharma’s CEO, was focused on the applications of 2OHOA as a potential innovative drug for the treatment of malignant brain tumours (glioma) and included preliminary results of the MIN-001-1203 clinical study currently on-going.

Palma de Mallorca, December 10th 2013–

Laminar Pharma presented yesterday 2OHOA as a new innovative drug for the potential treatment of glioma in the course of the final sessions of the European Venture Contest (EVC) 2013. 23 leading European biotech companies, previously selected among the most innovative and with the most promising prospects in the European biopharmaceutical market, presented their projects in front of a qualified panel of 28 European VC investors specialized in Biotech projects and directives of pharmaceutical companies, including GlaxoSmithKline (GSK), Boheringher Ingelheim (BI) or DSM. Laminar Pharma’s project was selected as one of the best 8 biotech projects in Europe in 2013.

The European Venture Summit is the final session of the prestigious European Venture Contest, organized by Europe Unlimited with the objective of finding, evaluating and awarding world-class innovative companies with the potential to dramatically impact their industry and contribute to increasing European competitiveness and growth by providing access to top-level international partners, advisors and financiers. The Contest, this year in its 9th edition, gathered over 800 companies and 600 venture capitalist and corporate investors from all over Europe. The Top 120 companies awarded at the qualifier events presented at the European Venture Summit and the Top 25 were selected.

The EVS was organised at the Congress Centre Düsseldorf and hosted by the City of Düsseldorf and the Ministry of Innovation, Science and Research of the German State of North Rhine Westphalia. The European Venture Summit was sponsored by NRW.Bank, Mobicap Ventures, and DealMarket and supported by BondPR and EMMINVEST. The Contest Jury, composed of 19 international investors and 28 investors with extensive experience in their respective fields elected the best 25 presenting companies (9 ICT, 8 life sciences and 8 cleantech) from more than 100 companies qualified through EVC 2013 Semi-Finals